{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:50:06Z","timestamp":1787759406803,"version":"build-2784847793"},"reference-count":44,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000038","name":"HHS | U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["75F4120C00111"],"award-info":[{"award-number":["75F4120C00111"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2023,4,18]]},"abstract":"<jats:p>\n            <jats:named-content content-type=\"genus-species\">Acinetobacter baumannii-<\/jats:named-content>\n            <jats:named-content content-type=\"genus-species\">Acinetobacter calcoaceticus<\/jats:named-content>\n            complex (referred to herein as\n            <jats:named-content content-type=\"genus-species\">A. baumannii<\/jats:named-content>\n            ) treatment guidelines contain numerous older antimicrobial agents with susceptibility test interpretive criteria (STIC, also known as susceptibility breakpoints) set using only epidemiological data. We utilized a combination of\n            <jats:italic>in vitro<\/jats:italic>\n            surveillance data, preclinical murine thigh and lung infection models, population pharmacokinetics, simulation, and pharmacokinetic\/pharmacodynamic (PK\/PD) target attainment analyses to evaluate\n            <jats:named-content content-type=\"genus-species\">A. baumannii<\/jats:named-content>\n            STIC for four commonly recommended antimicrobials from different classes (amikacin, ceftazidime, ciprofloxacin, and minocycline).\n          <\/jats:p>","DOI":"10.1128\/aac.01452-22","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T14:01:23Z","timestamp":1679493683000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":16,"title":["Development of Modernized Acinetobacter baumannii Susceptibility Test Interpretive Criteria for Recommended Antimicrobial Agents Using Pharmacometric Approaches"],"prefix":"10.1128","volume":"67","author":[{"given":"A. J.","family":"Lepak","sequence":"first","affiliation":[{"name":"University of Wisconsin\u2014Madison, Department of Medicine, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3468-3343","authenticated-orcid":true,"given":"M.","family":"Trang","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. P.","family":"Hammel","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7022-6644","authenticated-orcid":true,"given":"H. S.","family":"Sader","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4891-6467","authenticated-orcid":true,"given":"S. M.","family":"Bhavnani","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6527-1475","authenticated-orcid":true,"given":"B. D.","family":"VanScoy","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Pogue","sequence":"additional","affiliation":[{"name":"University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2230-1125","authenticated-orcid":true,"given":"P. G.","family":"Ambrose","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7927-9950","authenticated-orcid":true,"given":"D. R.","family":"Andes","sequence":"additional","affiliation":[{"name":"University of Wisconsin\u2014Madison, Department of Medicine, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"United States Committee on Antimicrobial Susceptibility Testing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","volume-title":"Antibiotic resistance threats in the United States, 2019.","author":"CDC","year":"2019","unstructured":"CDC. 2019. Antibiotic resistance threats in the United States, 2019. CDC, U.S. Department of Health and Human Services, Atlanta, GA."},{"key":"e_1_3_3_3_2","volume-title":"COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022.","author":"CDC","year":"2022","unstructured":"CDC. 2022. COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022. CDC, U.S. Department of Health and Human Services, Atlanta, GA."},{"key":"e_1_3_3_4_2","unstructured":"Fresenius Kabi USA LLC. 2019. Amikacin sulfate injection. Package insert. Fresenius Kabi Lake Zurich IL."},{"key":"e_1_3_3_5_2","unstructured":"Sagent Pharmaceuticals. 2020. Ceftazidime for injection. Package insert. Sagent Pharmaceuticals Schaumburg IL."},{"key":"e_1_3_3_6_2","unstructured":"Bayer HealthCare Pharmaceuticals. 2016. Cipro IV\u00ae. Package insert. Bayer HealthCare Pharmaceuticals Whippany NJ."},{"key":"e_1_3_3_7_2","unstructured":"Melinta Therapeutics LLC. 2021. Minocin. Minocycline for injection. Package insert. Melinta Therapeutics Lincolnshire IL."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/3527608001"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-019-03711-y"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa084"},{"key":"e_1_3_3_11_2","volume-title":"Performance standards for antimicrobial susceptibility testing; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2023","unstructured":"Clinical and Laboratory Standards Institute. 2023. Performance standards for antimicrobial susceptibility testing; approved standard, 33rd ed. CLSI document M100. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"33"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2016.11.008"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/158.4.831"},{"key":"e_1_3_3_14_2","unstructured":"The United States Committee on Antimicrobial Susceptibility Testing. 2019. Quinolone in vitro susceptibility test interpretive criteria evaluations. Version 1.3. http:\/\/www.uscast.org\/documents.html. Accessed 11 February 2023."},{"key":"e_1_3_3_15_2","unstructured":"The United States Committee on Antimicrobial Susceptibility Testing. 2019. Aminoglycoside in vitro susceptibility test interpretive criteria evaluations. Version 1.3. http:\/\/www.uscast.org\/documents.html. Accessed 11 February 2023."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa158"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00430-09"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.5.1065"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01809-20"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)70103-7"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-004-2171-2"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00133-06"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.119.4.1114"},{"key":"e_1_3_3_24_2","doi-asserted-by":"crossref","unstructured":"Lakota EA Rodvold KA Bhavnani SM Steenbergen JN Tzanis E Ambrose PG Rubino CM. 2017. A pharmacometric comparison of omadacycline and tigecycline epithelial lining fluid penetration abstr 63372. IDWeek 2017 San Diego CA.","DOI":"10.1093\/ofid\/ofx163.1380"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab1013"},{"key":"e_1_3_3_26_2","unstructured":"United States Food and Drug Administration. 2023. Antimicrobial susceptibility test interpretive criteria. https:\/\/www.fda.gov\/drugs\/development-resources\/antibacterial-susceptibility-test-interpretive-criteria. Accessed 11 February 2023."},{"key":"e_1_3_3_27_2","unstructured":"The United States Committee on Antimicrobial Susceptibility Testing. 2021. Breakpoint tables for interpretation of MIC and zone diameter results. Version 7.0. https:\/\/app.box.com\/s\/zmpi2qeh2wcs905b1fp9sjn06bf3jj4a. Accessed 11 February 2023."},{"key":"e_1_3_3_28_2","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. 2023. Breakpoint tables for interpretation of MICs and zone diameters. Version 13.0. https:\/\/www.eucast.org\/clinical_breakpoints\/. Accessed 11 February 2023."},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2017.09.009"},{"key":"e_1_3_3_30_2","unstructured":"Bulik CC Bhavnani SM Hammel J Forrest A Dudley MN Ellis-Grosse EJ Drusano GL Ambrose PG. 2013. Relationship between regulatory approval and pharmacokinetic-pharmacodynamic target attainment: focus on community- and hospital-acquired pneumonia abstr A-295. 53rd Intersci Conf Antimicrob Agents Chemother Denver Colorado."},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2017.06.002"},{"key":"e_1_3_3_32_2","doi-asserted-by":"crossref","unstructured":"Bhavnani SM Hammel JP Lakota EA Trang M Bader JC Bulik CC VanScoy BD Rubino CM Huband MD Friedrich L Steenbergen JN Ambrose PG. 2023. Pharmacokinetic-pharamcodynamic target attainment analyses evaluating omadacycline dosing regimens for treatment of patients with community-acquired bacterial pneumonia arising from Streptococcus pneumoniae and Haemophilus influenzae . Antimicrob Agents Chemother. AAC.02213-21. In press.","DOI":"10.1128\/aac.02213-21"},{"key":"e_1_3_3_33_2","unstructured":"Bhavnani SM Hammel JP Onufrak NJ Wicha WW Paukner S Sader HS Rubino CM Schranz J Gelone SP Ambrose PG. 2019. Pharmacokinetic-pharmacodynamic (PK-PD) target attainment analyses to support lefamulin dose justification and susceptibility breakpoint determinations for patients with community-acquired bacterial pneumonia (CABP) abstr P1946. 29th European Congress of Clinical Microbiology and Infectious Diseases Amsterdam Netherlands."},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01934-17"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.02.012"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02371-16"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01671-18"},{"key":"e_1_3_3_38_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","author":"CLSI","year":"2018","unstructured":"CLSI. 2018. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 11th ed. CLSI standard M07. Clinical and Laboratory Standards Institute, Wayne PA.","edition":"11"},{"key":"e_1_3_3_39_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2021. MIC distributions and the setting of epidemiological cut-off value (ECOFF) setting EUCAST SOP 10.2. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/EUCAST_SOPs\/2021\/EUCAST_SOP_10.2_MIC_distributions_and_epidemiological_cut-off_value__ECOFF__setting_20211202.pdf. Accessed 11 February 2023."},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2022.03.039"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1152\/jappl.1986.60.2.532"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.3109\/9781420017137.001"},{"key":"e_1_3_3_43_2","unstructured":"R Development Core Team. 2021. R version 4.0.4. R Foundation for Statistical Computing Vienna Austria."},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1973145852"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl224"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01452-22","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01452-22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T13:09:00Z","timestamp":1681823340000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01452-22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,18]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4,18]]}},"alternative-id":["10.1128\/aac.01452-22"],"URL":"https:\/\/doi.org\/10.1128\/aac.01452-22","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,18]]},"assertion":[{"value":"2022-10-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01452-22"}}